文献速递鼻科

变应性鼻炎患者报告结局量表(AR-PRO):中国的开发与验证

Patient-Reported Outcome Scale for Allergic Rhinitis (AR-PRO): Development and Validation in China.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-01-06

本研究旨在开发并验证适用于中国变应性鼻炎(AR)患者的患者报告结局量表(AR-PRO)。通过文献分析、病历回顾、访谈和专家小组讨论构建条目池,经两轮现场调查基于经典测验理论和项目反应理论(IRT)筛选条目,最终形成含20个条目、4个维度的量表,并在正式调查中评估其测量学性能。结果显示量表具有良好的信度、效度和可行性。

要点

  • AR-PRO包含20个条目,覆盖生理、心理、环境、满意度四个维度。
  • 量表Cronbach's α系数为0.910,重测组内相关系数(ICC)为0.950。
  • 量表应答率和完成率均为100%,平均完成时间380.4 ± 123.6秒。

核心结论

  • 20个条目的AR-PRO可能作为AR临床试验的可靠且科学的测量工具,因其表现出良好的信度、效度和可行性。

研究设计与样本

  • 通过文献分析、病历回顾、访谈和小组讨论开发概念框架并生成条目池,经专家和患者定性审查形成初始量表。
  • 进行两轮现场调查,基于经典测验理论和项目反应理论(IRT)筛选条目形成最终量表。
  • 进行正式调查评估AR-PRO的测量学性能。

主要发现

  • AR-PRO包含20个条目,覆盖生理、心理、环境和满意度四个维度。
  • Cronbach's α系数为0.910,两次AR-PRO测量间的组内相关系数(ICC)为0.950。
  • 内容效度、结构效度、效标效度和区分效度均达到相关标准。
  • 基于IRT的条目分析结果可接受。
  • 量表应答率和完成率均为100%,平均完成时间为380.4 ± 123.6秒。

关键数值与推荐

  • Cronbach's α系数为0.910。
  • 两次AR-PRO测量间的组内相关系数(ICC)为0.950。
  • 应答率和完成率均为100%。
  • 平均完成时间为380.4 ± 123.6秒。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcomes (PROs) have become indispensable measures in allergic rhinitis (AR) clinical trials. However, there is currently no scale specifically designed for the Chinese population. This study aimed to develop and validate the patient-reported outcome scale for allergic rhinitis (AR-PRO) to provide a reliable tool for AR patients in China. METHODS: We analyzed the relevant literature and medical records, and conducted interviews and panel discussions to develop the conceptual framework and generate the item pool. We subjected the collected items to removal, mergence, or modification to form the initial scale through a qualitative review by experts and patients. Subsequently, we conducted two field surveys to select items for the final scale based on the classical test theory and item response theory (IRT). Finally, we conducted a formal survey to assess the measurement properties of the AR-PRO. RESULTS: The AR-PRO comprised 20 items across four domains, including physiology, psychology, environment, and satisfaction. The Cronbach's α coefficient and intraclass correlation coefficient (ICC) between two AR-PRO-based measurements were 0.910 and 0.950, respectively. The content validity, structural validity, criterion validity, and discriminant validity all met relevant standards. The item analysis results based on IRT were acceptable. Both the response rate and completion rate of the scale were 100%, and the average completion time was 380.4 ± 123.6 s. CONCLUSION: The 20-item AR-PRO developed may be a reliable and scientific measure for AR clinical trials as it exhibited good reliability, validity, and feasibility.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Zhang P, Ren J, Chen T, et al. Patient-Reported Outcome Scale for Allergic Rhinitis (AR-PRO): Development and Validation in China. Int Forum Allergy Rhinol. 2025. PMID: 39761370. doi:10.1002/alr.23521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。